Navigation Links
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Date:12/9/2009

with the endoscopy procedures. The most commonly reported SAE following endoscopy was acute pancreatitis requiring hospitalization.

"Although this study did not achieve the pre-specified statistical outcome for the primary endpoint, it provides further evidence of the benefits of RG1068 in MRI imaging of the pancreas," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Further development plans for RG1068 will be determined following discussion of these results with the FDA next quarter."

This was a multi-center, baseline controlled, single dose study in which 258 patients with a history of pancreatitis at 23 clinical sites within the U.S. and Canada received an MRI of the pancreas with and without RG1068, and independently an endoscopic procedure called ERCP. The MRI imaging results were randomized and independently evaluated by three radiologists blinded to the details of the MRI procedures for evaluation of pancreatic duct abnormalities, image quality, number of duct segments visualized and confidence in diagnosis. The use of MRI is attractive for patient care as it can obviate the need for more risky invasive procedures such as ERCP.

RG1068 is a synthetic version of human secretin, a natural gastrointestinal hormone involved in the process of digestion. Secretin has been used for many years by gastroenterologists in conjunction with ERCP, an invasive procedure to evaluate and treat diseases of the pancreas and gallbladder. There are risks associated with the use of ERCP, which have generated interest in the development of safer non-invasive tests to diagnose gastrointestinal disorders. The use of RG1068 in combination with a non-invasive procedure such as MRI can improve the detection of abnormalities and increase the diagnostic quality of the MRI image of the pancreas. The FDA has granted RG1068 Orphan Drug status and Fast Track Designation, a process designed to facilitate the deve
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
2. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
3. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
4. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
5. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
8. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
9. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
10. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
11. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 Based on ... Frost & Sullivan recognises ADOCIA with the 2014 ... Leadership. By adopting a flexible business model that ... the pharmaceutical industry, ADOCIA has managed to maintain ... proteins space. "ADOCIA,s core technology is ...
(Date:9/29/2014)... , Sept. 29, 2014  On Oct. 2, ... participate in the company,s seventh Global Day of Service. ... employees will join together in a single, coordinated effort ... play. "I,m so proud of this ... talent and energy to strengthening the communities around the ...
(Date:9/29/2014)... 2014 Kush Bottles, North America,s ... and consulting services for the medical and recreational marijuana ... has assumed the role of Chief Executive Officer. ... and worked as COO until February of 2014, returned ... other ventures. His return marks a clear dedication to ...
Breaking Medicine Technology:Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins 2Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins 3Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins 4Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins 5Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins 6Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries 2Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries 3Kush Bottles Co-Founder Steps into Role of CEO 2
... Target Enrollment Expected in Fourth Quarter, BERKELEY ... GNTA ) announced that the Data Safety Monitoring ... Genasense (oblimersen sodium),Injection, which is the Company,s lead ... as originally planned after initial review of,blinded safety ...
... unique Ranexa(R) mechanism of action -, CHICAGO, March ... today that ranolazine significantly (p<0.001),shortened the QT interval of ... LQT3, which is caused by a genetic mutation in ... rhythm problems, including,sudden death. Ranolazine also shortened cardiac relaxation ...
Cached Medicine Technology:DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 2DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 3DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 4Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 2Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 3
(Date:9/30/2014)... Pyramid Analytics, worldwide leader in Governed ... of Veterans Affairs has selected Pyramid Analytics ... Business Intelligence platform. This partnership will enable the ... enabling more than 30,000 users with insights that ... and reporting capabilities. , The strategic selection comes ...
(Date:9/30/2014)... “Biology and botany are having ... “and it’s about naming rights.” , In ... on the Bryan William Brickner Blog, the focus ... of Health (PubMed). The post highlights five cannabinoid ... transitions, aging with THC, the wake-inducing effects of ...
(Date:9/30/2014)... September 30, 2014 A trailblazer at heart, ... seeks out upcoming medical breakthroughs in spine repairs. His ... seen in his patients in which he has implanted the ... its components are state-of-the art and mimic normal human disc ... has also been proven to be an exceptional replacement device ...
(Date:9/30/2014)... 30, 2014 3M has added four new ... bond tapes. 3M 5906 , 3M 5907 , ... conformable VHBs which help create the strongest bond possible to ... used for bonding to difficult surfaces such as paints, low ... 5907, 5908, and 5905 are designed specifically for electronic device ...
(Date:9/30/2014)... Dogs are social animals, and love to go everywhere with ... travelling from place to place. Many dog owners choose to ... this is not only unsafe for the dog, but unsafe ... shares with readers why keeping a dog restrained in a ... ways a dog can become injured by riding freely in ...
Breaking Medicine News(10 mins):Health News:U.S. Department of Veterans Affairs Takes Its Analytic Capabilities to the Next Level with BI Office from Pyramid Analytics 2Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 2Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 3
... ... , ... , ... ...
... The adverse affects of being overweight are not limited to ... research in the latest issue of the Journals ... (Volume 65A, Number 1). The publication presents a collection ... older persons. "One of the unanticipated consequences of ...
... exposure time , TUESDAY, Feb. 23 (HealthDay News) -- ... as much as 91 percent less radiation than standard ... generated great enthusiasm in recent years, due to its ... coronary artery disease. However, that enthusiasm has been tempered ...
... to develop dementia than non-hospitalized, study finds , TUESDAY, ... hospitalized have an increased risk of cognitive decline. , That,s ... through 2007 on 2,929 people, aged 65 and older, who ... During an average follow-up of 6.1 years, 1,287 were hospitalized ...
... ... ... ... ...
... stress hormone levels in adolescent boys and girls but ... researchers. Early treatment of depression could help reduce stress ... "This is the first time cortisol reactivity has ... obesity in girls," said Elizabeth J. Susman, the Jean ...
Cached Medicine News:Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 2Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 3Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 4Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 5Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 6Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 7Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 8Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 9Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 10Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 11Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 12Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 13Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 14Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 15Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 16Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 17Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 18Health News:Overweight middle-aged adults at greater risk for cognitive decline in later life 2Health News:New Heart CT Scans Deliver Far Less Radiation: Study 2Health News:Hospital Stays May Spur Brain Decline in Seniors 2Health News:Stopain Labels Featuring Arthritis Foundation Sponsorship Now Appearing on Retail Shelves 2Health News:Stopain Labels Featuring Arthritis Foundation Sponsorship Now Appearing on Retail Shelves 3Health News:Stopain Labels Featuring Arthritis Foundation Sponsorship Now Appearing on Retail Shelves 4Health News:Stress hormone, depression trigger obesity in girls 2
... Elite II features a diagnostic ... of Glasgow,(UG) algorithm. Unlike competitive ... age, the UG,algorithm bases its ... gender, age, race, medication,and classification., ...
... test face is a LogMAR ... Landolt C in various orientations ... targets are presented at 10% ... useful for evaluating the low ...
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
... test face is used widely for screening ... LogMAR acuity from 20/10 to 20/100 and ... cycles/degree. , ,The patient can be easily ... acuity and contrast sensitivity. If a contrast ...
Medicine Products: